L & S Advisors Inc Sells 7,793 Shares of AbbVie Inc. $ABBV

L & S Advisors Inc lessened its position in AbbVie Inc. (NYSE:ABBV) by 18.2% during the 4th quarter, HoldingsChannel.com reports. The fund owned 35,064 shares of the company’s stock after selling 7,793 shares during the period. L & S Advisors Inc’s holdings in AbbVie were worth $8,012,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also recently bought and sold shares of the company. Soltis Investment Advisors LLC raised its holdings in AbbVie by 55.0% in the 4th quarter. Soltis Investment Advisors LLC now owns 34,077 shares of the company’s stock worth $7,786,000 after acquiring an additional 12,096 shares during the period. Ranch Capital Advisors Inc. raised its holdings in AbbVie by 3.1% in the 4th quarter. Ranch Capital Advisors Inc. now owns 10,871 shares of the company’s stock worth $2,484,000 after acquiring an additional 322 shares during the period. Guardian Capital LLC bought a new position in AbbVie in the 4th quarter worth $355,000. Evergreen Wealth Partners LLC bought a new position in AbbVie in the 4th quarter worth $422,000. Finally, Disciplined Investments LLC bought a new position in AbbVie in the 4th quarter worth $233,000. Institutional investors own 70.23% of the company’s stock.

AbbVie Stock Performance

NYSE:ABBV opened at $210.54 on Friday. The firm’s 50-day moving average is $210.27 and its 200-day moving average is $220.10. AbbVie Inc. has a 52-week low of $180.25 and a 52-week high of $244.81. The company has a market cap of $371.98 billion, a price-to-earnings ratio of 103.71, a PEG ratio of 0.73 and a beta of 0.32.

AbbVie (NYSE:ABBV) last posted its quarterly earnings data on Wednesday, April 29th. The company reported $2.65 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.59 by $0.06. AbbVie had a net margin of 5.79% and a negative return on equity of 576.45%. The company had revenue of $15 billion for the quarter, compared to the consensus estimate of $14.72 billion. During the same quarter in the previous year, the firm posted $2.46 EPS. The business’s revenue was up 12.4% compared to the same quarter last year. Equities analysts predict that AbbVie Inc. will post 14.3 EPS for the current year.

AbbVie Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Friday, May 15th. Stockholders of record on Wednesday, April 15th were given a dividend of $1.73 per share. This represents a $6.92 annualized dividend and a dividend yield of 3.3%. The ex-dividend date was Wednesday, April 15th. AbbVie’s payout ratio is 340.89%.

More AbbVie News

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: AbbVie’s Q1 results were supported by strong sales of Skyrizi and Rinvoq, which helped offset ongoing Humira declines and boosted the company’s 2026 guidance. Article: How Important Are Skyrizi and Rinvoq to AbbVie’s Q1 Results?
• Positive Sentiment: Analysts have turned more optimistic on AbbVie’s earnings power, with Erste Group raising FY2027 EPS estimates and the company’s long-term pipeline still viewed favorably.
• Positive Sentiment: Recent commentary highlighted AbbVie as a potentially better growth story than AstraZeneca because of its valuation, dividend profile, and pipeline strength. Article: Which Pharma Giant Offers Better Growth: AstraZeneca or AbbVie?

Insider Activity

In other news, SVP David Ryan Purdue sold 5,230 shares of AbbVie stock in a transaction dated Wednesday, March 4th. The shares were sold at an average price of $233.56, for a total transaction of $1,221,518.80. Following the sale, the senior vice president directly owned 2,654 shares in the company, valued at approximately $619,868.24. The trade was a 66.34% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Perry C. Siatis sold 22,381 shares of AbbVie stock in a transaction dated Wednesday, February 25th. The shares were sold at an average price of $230.00, for a total transaction of $5,147,630.00. Following the sale, the executive vice president owned 38,137 shares in the company, valued at approximately $8,771,510. This trade represents a 36.98% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. 0.06% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

Several research analysts recently commented on the stock. Sanford C. Bernstein reiterated a “market perform” rating on shares of AbbVie in a report on Thursday, February 5th. Evercore set a $235.00 price objective on shares of AbbVie in a report on Friday. BMO Capital Markets restated an “outperform” rating on shares of AbbVie in a report on Monday, March 9th. Weiss Ratings restated a “hold (c)” rating on shares of AbbVie in a report on Wednesday, January 21st. Finally, Cantor Fitzgerald restated an “overweight” rating and set a $240.00 price objective on shares of AbbVie in a report on Thursday, April 30th. Three research analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and six have assigned a Hold rating to the company. According to MarketBeat.com, AbbVie presently has a consensus rating of “Moderate Buy” and an average price target of $253.43.

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.